Clinical Trials News
February 25th, 2010
A new drug developed to battle osteoporosis has been found to reduce the risk of fractures and the risk of some breast cancers, heart disease and stroke, according to new research.
However, similar to other osteoporosis treatments already available, the drug (called Lasofoxifene) also raises the risk of blood clots, the researchers discovered. Lasofoxifene, also known [...]
January 18th, 2010
Angiotensin receptor blockers, prescription drugs commonly used to treat high blood pressure and heart disease, may help reduce the risk of Alzheimer’s disease and dementia, new research is suggesting.
The study also demonstrated that angiotensin receptor blockers appear to provide a higher level of protection against Alzheimer’s disease and dementia in comparison to other high blood [...]
December 24th, 2009
Similar to the mistake that made Pfizer millions, an experimental drug that was tested as an antidepressant may actually increase sexual desire and the number of satisfying sexual encounters in women.
Research, presented in France, introduced the drug flibanserin at a Congress for Sexual Medicine. Fans of this drug, called Flibanserin, have hailed it as the [...]
December 23rd, 2009
Members of the U.S. Food and Drug administration have decided that use of the cholesterol pill, Crestor, for patients with normal cholesterol levels will aid in preventing heart attack, stroke and death.
The select panel of experts came to the decision after a vote of 12-4 concerning the prescription drug’s benefits. The conclusion supported the idea [...]
September 10th, 2009
GlaxoSmithKline recently advised the public that the US FDA’s Vaccines and Related Biological Products Advisory Committee voted that Ceravix, the company’s cervical cancer vaccine, presented data that substantiates the efficacy and safety of the treatment.
August 19th, 2009
A recent study proclaims that patients who require a blood stem-cell transplant may be able to lessen the risk of graft-versus-host disease (GVHD - transplanted materials attack the body), thanks to ant-T-cell globulin treatment.
August 17th, 2009
After Benlysta achieved the primary endpoint in Bliss - 52, Human Genome Sciences, is pleased report that the first two pivotal Phase 3 trials involving patients with serologically active systematic lupus erythematous has been completed. The results have began to prove that Benlysta may in fact possess the potential to become the first approved systematic lupus treatment in decades.
August 17th, 2009
The US FDA has approved Saphris sublingual tablets for the acute therapy of schizophrenic adults, as well as the acute therapy of manic or mixed bipolar I disorder, with or without adult psychotic attributes. Saphris is endorsed for first-line therapy, and is the first prescription drug to receive primary consent for both of these symptoms concurrently.
August 13th, 2009
Specialty pharmaceutical company, who specializes in the generation of revolutionary products to treat neurological and psychiatric diseases, publicizes top-line results from the Phase III Zelrix clinical tria
August 11th, 2009
Sanofi-aventis recently publicized the release of an Expert Statement issued by a board of multidisciplinary, internationally acclaimed experts, which follows an in-depth evaluation of the recent publications of registry analyses with Lantus in Diabetologia.
